Skip to Content
MilliporeSigma
All Photos(1)

Documents

1098184

USP

Ceftriaxone sodium

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Ceftriaxone disodium salt hemi(heptahydrate)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H16N8Na2O7S3 · 3.5H2O
CAS Number:
104376-79-6
Molecular Weight:
661.60
MDL number:
MFCD01750405
UNSPSC Code:
41116107
PubChem Substance ID:
329749258
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ceftriaxone

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

InChI key

PMRZKYOXTPBIQF-MAODNAKNSA-J

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ceftriaxone sodium USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Ceftriaxone for Injection
  • Ceftriaxone Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ning Li et al.
Pediatrics, 133(4), e917-e922 (2014-03-26)
Our aim was to evaluate the clinical profile, treatment, and outcome of ceftriaxone-associated postrenal acute renal failure (PARF) in children. We retrospectively studied 31 consecutive cases from 2003 to 2012 for PARF after ceftriaxone treatment. There was no past history
Yi Yao et al.
Pharmacoepidemiology and drug safety, 21(11), 1197-1201 (2012-07-05)
The incidence of adverse reactions to ceftriaxone, which is widely used in China, has gradually increased, with an associated increase in patient fatality. An analysis of the reported data from articles published in China highlights the importance and extent of
Emphysematous pyelitis.
Kendall Luyt et al.
The Journal of pediatrics, 166(1), 201-201 (2014-10-01)
Anthony R Flores et al.
The Journal of infectious diseases, 209(10), 1520-1523 (2013-12-07)
Invasive group A streptococcal (GAS) strains often have genetic differences compared to GAS strains from nonsterile sites. Invasive, "hypervirulent" GAS strains can arise from a noninvasive progenitor following subcutaneous inoculation in mice, but such emergence has been rarely characterized in
Dafydd Loughran et al.
Journal of clinical pathology, 67(5), 445-448 (2014-01-25)
This case report details the second described case of Whipple's disease-related thrombocytopenia in the medical literature. Whipple's disease is a rare multisystem infection caused by the actinomycete Tropheryma whipplei, first described by George Whipple in 1907. The key clinical manifestations
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service